Table 1 Baseline variables in patients treated with ACP or RIVP + ACP during TARS

Demographics

 Age

45 ± 10

47 ± 10

 Male, n (%)

30 (79)

35 (92)

 Ethnicity, n (%)

  Han ^a

36 (95)

37 (97)

  Tibetan ^a

1 (3)

1 (3)

  Other ^a

1 (3)

0 (0.0)

 Body mass index, kg/m²

24.64 ± 3.71

25.51 ± 3.20

 Current smoker, n (%)

20 (53)

18 (47)

 Current drinker, n (%)

5 (13)

6 (16)

 EuroScore II, median (IQR)

2.49 (2.38, 4.12)

2.68 (1.98, 3.86)

Circulatory system

 Hyperlipemia, n (%)^a

1 (3)

1 (2.6)

 Hypertension, n (%)

27 (71)

21 (55)

 Ejection fraction, %

60 ± 9

60 ± 8

 Arrhythmia, n (%)^a

0 (0)

1 (3)

 Cardiovascular intervention, n (%)

4 (11)

2 (5)

Respiratory system

 Respiratory failure, n (%)^a

1 (3)

0 (0.0)

 Infection, n (%)^a

1 (3)

0 (0.0)

 Atelectasis, n (%)^a

1 (3)

2 (5)

 Pleural effusion, n (%)

6 (16)

8 (21)

Nervous system, n (%)

 Transient ischemic attack ^a

0 (0.0)

1 (3)

 Stroke history ^a

0 (0.0)

3 (8)

 Renal failure (RIFLE III) ^a

0 (0.0)

0 (0)

 Diabetes, n (%)^a

1 (3)

0 (0.0)

 Hypothyroidism, n (%)^a

4 (11)

5 (13)

 Liver dysfunction, n (%)^a

1 (3)

2 (5)

 Gastrointestinal bleeding, n (%)^a

1 (3)

1 (3)

 Ulcer, n (%)^a

2 (5)

0 (0)

Laboratory index

 Hemoglobin (g/L)

134 ± 17

132 ± 18

 Platelets (× 10⁹/L)

162 ± 72

187 ± 96

 Leukocytes (× 10⁹/L)

10.30 ± 3.23

10.72 ± 3.56

 International normalized ratio

1.02 (0.97, 1.12)

1.02 (0.97, 1.10)

 Fibrinogen (g/dL)

3.45 ± 1.60

3.96 ± 1.75

 Glucose (mmol/L)

6.14 ± 1.09

6.46 ± 1.02

 C-reactive protein (mg/L)

40.8 (11.5, 86.0)

77.5 (36.3, 101.2)

 Troponin-T (ng/L)

16.1 (9.9, 43.9)

20.1 (12.8, 34.2)

 Creatinine level (umol/L)

 ≤ 110

28(74)

30(79)

 110–176

9(24)

8(21)

 ≥ 176

1(3)

0(0)

Medicine, n (%)

 Beta blocker

33 (87)

32 (84)

Aspirin

1(3)

1 (3)

 Anticoagulants

1 (3)

0 (0)